| Lindsey Marie Espinosa-arnold, RN | |
|
600 South Choctaw, El Reno, OK 73036 | |
| (405) 422-6327 | |
| Not Available |
| Full Name | Lindsey Marie Espinosa-arnold |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Psychiatric/mental Health, Child & Adolescent |
| Location | 600 South Choctaw, El Reno, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427701978 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WP0807X | Registered Nurse - Psychiatric/mental Health, Child & Adolescent | R0101645 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lindsey Marie Espinosa-arnold, RN Po Box 1280, Bethany, OK 73008-1280 Ph: () - | Lindsey Marie Espinosa-arnold, RN 600 South Choctaw, El Reno, OK 73036 Ph: (405) 422-6327 |
News Archive
Our brains seem to reduce sensory perception from an area of our skin when we touch it ourselves, according to a new study from Linköping University published in the journal Proceedings of the National Academy of Sciences, PNAS.
Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.
A team of University of Arkansas for Medical Sciences research scientists recently received a $422,610 grant from the National Science Foundation to study the mechanisms of control of emotional responses of men and women using functional magnetic resonance imaging (fMRI).
Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to better treatment of this invasive and deadly cancer, according to Penn State College of Medicine researchers in The Foreman Foundation Research Laboratory.
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
› Verified 2 days ago
Ryleigh Blair Collier, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 600 S Choctaw Ave, El Reno, OK 73036 Phone: 405-422-6327 | |
Rebecca Decker, RN, IBCLC Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 9897 S Brandley Rd, El Reno, OK 73036 Phone: 405-213-8353 | |
Cynthia Barnett, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 7777 E Us Highway 66, El Reno, OK 73036 Phone: 405-422-8800 | |
Kelly Rae Bingham, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1631-a East Highway 66, El Reno, OK 73036 Phone: 405-262-7631 Fax: 405-262-8099 | |
Taylor Horton, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 7777 E Us Highway 66, El Reno, OK 73036 Phone: 405-424-7711 | |
Ms. Peggy Ruth Immohotichey, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1631 E Us Highway 66, El Reno, OK 73036 Phone: 405-262-7631 Fax: 405-262-8099 | |
Mr. Kieran Michael Donahue, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 7777 E Us Highway 66, El Reno, OK 73036 Phone: 405-422-8800 |